Characterizing microglial gene expression in a model of secondary progressive multiple sclerosis
Sign Up to like & getrecommendations! Published in 2022 at "Glia"
DOI: 10.1002/glia.24297
Abstract: Multiple sclerosis (MS) is the most common inflammatory, demyelinating and neurodegenerative disease of the central nervous system in young adults. Chronic‐relapsing experimental autoimmune encephalomyelitis (crEAE) in Biozzi ABH mice is an experimental model of MS.… read more here.
Keywords: secondary progressive; expression; model; phase ... See more keywords
Predicting onset of secondary-progressive multiple sclerosis using genetic and non-genetic factors
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Neurology"
DOI: 10.1007/s00415-020-09850-z
Abstract: Background Predicting the transition from relapsing–remitting (RR) to secondary-progressive (SP) multiple sclerosis (MS) from early in the disease course is challenging. Objective To construct prediction models for SPMS using sociodemographic and self-reported clinical measures that… read more here.
Keywords: symptomatology; risk; progressive multiple; multiple sclerosis ... See more keywords
Unraveling diagnostic uncertainty in transition phase from relapsing-remitting to secondary progressive multiple sclerosis.
Sign Up to like & getrecommendations! Published in 2020 at "Multiple sclerosis and related disorders"
DOI: 10.1016/j.msard.2020.102211
Abstract: Abstract Background Clinicians struggle to timely diagnose secondary-progressive multiple sclerosis (SP-MS), with a ‘transition phase’ period of diagnostic uncertainty. We aimed at defining clinical markers predicting evolution to SP-MS. Methods : We reviewed 210 newly… read more here.
Keywords: transition phase; progressive multiple; diagnostic uncertainty; secondary progressive ... See more keywords
Early predictors of conversion to secondary progressive multiple sclerosis.
Sign Up to like & getrecommendations! Published in 2021 at "Multiple sclerosis and related disorders"
DOI: 10.1016/j.msard.2021.103115
Abstract: BACKGROUND We conducted this study to estimated the time of conversion from relapsing-remitting MS (RRMS) to SPMS and its early predictor factors. METHODS In this retrospective study, demographic, clinical, and imaging data from MS patients… read more here.
Keywords: predictors conversion; progressive multiple; early predictors; multiple sclerosis ... See more keywords
Application of definitions for conversion to secondary progressive MS in a Danish nationwide population.
Sign Up to like & getrecommendations! Published in 2021 at "Multiple sclerosis and related disorders"
DOI: 10.1016/j.msard.2021.103319
Abstract: BACKGROUND The number of patients with relapsing remitting multiple sclerosis (RRMS) who convert to secondary progressive (SP) MS is uncertain, and with emerging treatment options for SPMS, it is important to identify RRMS patients in… read more here.
Keywords: spms; secondary progressive; disease modifying; multiple sclerosis ... See more keywords
To stop or not to stop disease modifying therapies in secondary progressive multiple sclerosis, that is the question
Sign Up to like & getrecommendations! Published in 2017 at "Expert Review of Neurotherapeutics"
DOI: 10.1080/14737175.2017.1340831
Abstract: The predominant clinical disease course of multiple sclerosis (MS) which can be treated today by a variety of different disease-modifying treatments (DMT) is characterized by reversible episodes of neurological disability (relapsing remitting form of MS… read more here.
Keywords: treatment; disease modifying; disease; multiple sclerosis ... See more keywords
Current therapeutic landscape in multiple sclerosis: an evolving treatment paradigm
Sign Up to like & getrecommendations! Published in 2019 at "Current Opinion in Neurology"
DOI: 10.1097/wco.0000000000000700
Abstract: Purpose of review To critically assess the current landscape of disease-modifying agents for multiple sclerosis (MS). Treatment algorithms will be discussed and studies for new agents in late development or recently approved are analyzed in… read more here.
Keywords: landscape; treatment; current therapeutic; secondary progressive ... See more keywords
Autologous haematopoietic stem cell transplantation versus low‐dose immunosuppression in secondary–progressive multiple sclerosis
Sign Up to like & getrecommendations! Published in 2022 at "European Journal of Neurology"
DOI: 10.1111/ene.15280
Abstract: Effectiveness of autologous haematopoietic stem cell transplantation (AHSCT) in relapsing–remitting multiple sclerosis (MS) is well known, but in secondary–progressive (SP)‐MS it is still controversial. Therefore, AHSCT activity was evaluated in SP‐MS using low‐dose immunosuppression with… read more here.
Keywords: haematopoietic stem; stem cell; secondary progressive; cell transplantation ... See more keywords
Cognitive function in primary and secondary progressive multiple sclerosis: a multiparametric MRI study.
Sign Up to like & getrecommendations! Published in 2023 at "European journal of neurology"
DOI: 10.1111/ene.15900
Abstract: BACKGROUND The differences in cognitive function between primary progressive (PP) and secondary progressive (SP) multiple sclerosis (MS) remain unclear. We compared cognitive performance between PPMS and SPMS, and explored the structural and functional MRI correlates… read more here.
Keywords: ppms spms; secondary progressive; function primary; cognitive function ... See more keywords
Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis
Sign Up to like & getrecommendations! Published in 2018 at "BMJ Open"
DOI: 10.1136/bmjopen-2018-021944
Abstract: Introduction The major unmet need in multiple sclerosis (MS) is for neuroprotective therapies that can slow (or ideally stop) the rate of disease progression. The UK MS Society Clinical Trials Network (CTN) was initiated in… read more here.
Keywords: trial; efficacy; multiple sclerosis; arm ... See more keywords
Evaluation of neurological changes in secondary progressive multiple sclerosis patients treated with immune modulator MIS416: results from a feasibility study
Sign Up to like & getrecommendations! Published in 2017 at "Pilot and Feasibility Studies"
DOI: 10.1186/s40814-017-0201-4
Abstract: BackgroundWhile disease progression can be readily monitored in early stage relapsing multiple sclerosis (MS), it is more challenging for secondary progressive multiple sclerosis (SPMS). This advanced stage of disease has distinct pathophysiology due to compartmentalization… read more here.
Keywords: status; sclerosis; trial; multiple sclerosis ... See more keywords